REDWOOD CITY, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that John Nicols, President & CEO, will discuss the development of an improved DNA ligase for the molecular diagnostics industry during the “Next-Generation Sequencing in Precision Medicine” session at the 25thInternational Molecular Medicine Tri-Conference. Nicols will present “An Engineered DNA Ligase for Efficient Conversion of Input DNA during NGS Library Preparation” today at 1:10 p.m. Pacific time. The conference is being held February 12-14, 2018 in San Francisco.
“Molecular diagnostics next generation sequencing (NGS) assays are critically dependent on efficient conversion of low-concentration DNA samples to sequencing-capable fragments via adapter ligation,” said Nicols. “Codexis has developed an engineered DNA ligase to achieve exceptional conversion of low-concentration input DNA with improved reaction kinetics relative to commercially available T4 ligase, while maintaining low adapter dimerization activity. The Codexis Performance DNA Ligase is ideally suited for NGS IVD applications, where it will improve assay sensitivity and increase workflow flexibility and robustness. We’re delighted to discuss our new high-performance enzyme with the many thought leaders in diagnostics attending this conference.”
Codexis is expanding into the molecular diagnostics industry by developing and commercializing proprietary, high-performance enzymes for use in NGS and polymerage chain reaction (PCR/qPCR). The company is using its CodeEvolver® protein engineering platform to rapidly develop highly optimized enzymes for use by molecular diagnostics customers to improve the sensitivity and precision of their diagnostic tests.
About the Molecular Medicine Tri-Conference
Since its debut in 1993, the annual Molecular Medicine Tri-Conference has become one of the world’s leading international events in the field of drug discovery, development and diagnostics. The Tri-Conference unites an ecosystem of 3,700 innovative thinkers and thought leaders throughout biotech, pharma and academia from around the world.
About Codexis, Inc.
Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for commercial manufacture of pharmaceuticals and fine chemicals, as well as the development of enzymes as biotherapeutics and for molecular diagnostics. Codexis’ proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. For more information, see www.codexis.com.
To the extent that statements contained in this press release are not descriptions of historical facts regarding Codexis, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding Codexis’ development of an engineered DNA ligase for NGS IVD applications and its anticipated performance and benefits. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Codexis’ control and that could materially affect actual results. Factors that could materially affect actual results include, among others: Codexis’ dependence on its licensees and collaborators; Codexis’ dependence on a limited number of products and customers in its biocatalysis business; potential adverse effects to Codexis’ business if its customers’ pharmaceutical or food products are not received well in the markets; risks, uncertainties and costs associated with the successful development of biotherapeutic candidates, including obtaining development partners for its biotherapeutic programs and progressing such programs to clinical trials and regulatory approvals; Codexis’ ability to develop and commercialize new products for the biocatalysis markets; Codexis’ dependence on a limited number of contract manufacturers for large-scale production of its enzymes; Codexis’ ability to deploy its technology platform in new market spaces, including the fine chemicals, therapeutics and in vitro molecular diagnostics markets; Codexis’ ability to comply with the terms of its credit facility and its associated debt service obligations; Codexis’ need for additional capital in the future in order to expand its business or to adjust for market conditions or strategic considerations, which may involve Codexis entering into equity offerings, debt financings, credit facilities and/or strategic collaborations; Codexis’ dependence on key personnel; Codexis’ ability to establish and maintain adequate protection for intellectual property, trade secrets and other proprietary rights covering its technologies; and any claims by third parties that Codexis is infringing their intellectual property rights or other proprietary rights. Additional information about factors that could materially affect actual results can be found in Codexis’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 9, 2017 and Form 10-Q filed November 9, 2017, including under the caption “Risk Factors” and in Codexis’ other current and periodic reports filed with the SEC. Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
LHA Investor Relations
Jody Cain, 310-691-7100
Source: Codexis, Inc.